vimarsana.com

Page 71 - எங்களுக்கு ப்ரெவெஂடிவ் சேவைகள் பணி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A Colonoscopy Alternative Comes Home

Exact Sciences Announces Preliminary Fourth Quarter 2020 Results

Exact Sciences Announces Preliminary Fourth Quarter 2020 Results - Expected total revenue of $464.5-467.5M, including Screening revenue of $249-250M, Precision Oncology revenue of $117-118M, and COVID-19 testing revenue of $98.5-99.5M News provided by Share this article Share this article MADISON, Wis., Jan. 10, 2021 /PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020. I m incredibly proud of how the Exact Sciences team came together during 2020 to make progress towards our mission of eradicating cancer and the suffering it causes, said Kevin Conroy, chairman and CEO of Exact Sciences. Following our combination with Thrive, we are confident in making blood-based, multi-cancer screening a reality and being a leading provider of earlier, smarter cancer tests for patients at every step of their journey. We ve never been more excited abo

Many health plans now must cover full cost of expensive HIV prevention drugs

Ted Howard started taking Truvada a few years ago because he wanted to protect himself against HIV, the virus that causes AIDS. But the daily pill was so pricey he was seriously thinking about giving it up. Under his insurance plan, the former flight attendant and customer service instructor owed $500 in copayments every month for the drug and an additional $250 every three months for lab work and clinic visits. Advertisement: Luckily for Howard, his doctor at Las Vegas Huntridge Family Clinic, which specializes in LGBTQ care, enrolled him in a clinical trial that covered his medication and other costs in full.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.